Venture-Backed Inotek Targets $100M In IPO, Note Offering
Inotek Pharmaceuticals Corp., a venture capital-backed biotechnology company developing an eye drop treatment for glaucoma, set terms for its initial public offering and fine-tuned plans for a concurrent note offering Thursday,...To view the full article, register now.
Already a subscriber? Click here to view full article